(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 August 2013 (29.08.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/124826 A1

(51) **International Patent Classification**:
C07D 413/14 (2006.01) ***A61P 35/00*** (2006.01)
A61K 31/5377 (2006.01)

(21) **International Application Number**:
PCT/IB2013/051443

(22) **International Filing Date**:
22 February 2013 (22.02.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/602,954 24 February 2012 (24.02.2012) US
61/736,707 13 December 2012 (13.12.2012) US

(71) **Applicant**: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors**: **CARAVATTI, Giorgio**; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **FAIRHURST, Robin Alec**; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **FURET, Pascal**; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **STAUFFER, Frédéric**; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **SEILER, Frank Hans**; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **RUEEGER, Heinrich**; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **MCCARTHY, Clive**; Evotec, 114 Milton Park, Abington Oxfordshire OX14 4SA (GB).

(74) **Agent**: **DYER, James**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2013/124826 A1

(54) **Title**: OXAZOLIDIN- 2 -ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS

(57) **Abstract**: The present invention relates to oxazolidin-2-one subsituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.